Next Article in Journal
Investigation of Nano-Bio Interactions within a Pancreatic Tumor Microenvironment for the Advancement of Nanomedicine in Cancer Treatment
Previous Article in Journal
Lung Cancer Inequalities in Stage of Diagnosis in Ontario, Canada
Case Report

A Case of Pathological Complete Response and Resolution of Dermatomyositis Following Neoadjuvant Chemotherapy in HER2-Positive Early Breast Cancer

1
Oncology Unit, Department of Clinical and Molecular Medicine, Sant’Andrea Hospital, University “La Sapienza”, 00189 Rome, Italy
2
Neuromuscular and Rare Disease Centre, Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), SAPIENZA University of Rome, Sant’Andrea Hospital, 00189 Rome, Italy
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2021, 28(3), 1957-1961; https://doi.org/10.3390/curroncol28030182
Received: 20 March 2021 / Revised: 7 May 2021 / Accepted: 19 May 2021 / Published: 24 May 2021
Introduction. Dermatomyositis (DM) is an idiopathic inflammatory myopathy (IIM) mainly characterized by subacute muscle weakness and skin rash sometimes associated with malignancy. Case Presentation. A 61-year-old female was admitted to our hospital because of progressive proximal muscular weakness, heliotropic rash and left breast rash. Muscle biopsy findings were consistent with dermatomyositis (DM). A full panel of myositis associated (MAA) and specific antibodies (MSA) revealed the presence of anti-nuclear antibodies (1:160, speckled), Anti-Ro52 and anti TIF1-γ antibodies. A whole body Computed Tomography Scan showed three left mammary nodules and homolateral axillary lymphadenopathy. The breast biopsy confirmed the diagnosis of ductal carcinoma. Patient was initiated to neoadjuvant chemotherapy followed by surgery for cancer, and corticosteroid and intravenous immunoglobulins for DM with a complete resolution of muscle weakness and pathological complete response of breast cancer. Discussion and conclusion. Similar cases in literature are commonly referred to a first-line surgery and the role of neoadjuvant chemotherapy is debatable. View Full-Text
Keywords: dermatomyositis; paraneoplastic; breast cancer; neoadjuvant chemotherapy; trastuzumab dermatomyositis; paraneoplastic; breast cancer; neoadjuvant chemotherapy; trastuzumab
Show Figures

Figure 1

MDPI and ACS Style

Piras, M.; Panebianco, M.; Garibaldi, M.; Roberto, M.; Merlonghi, G.; Pellegrini, P.; Marchetti, P. A Case of Pathological Complete Response and Resolution of Dermatomyositis Following Neoadjuvant Chemotherapy in HER2-Positive Early Breast Cancer. Curr. Oncol. 2021, 28, 1957-1961. https://doi.org/10.3390/curroncol28030182

AMA Style

Piras M, Panebianco M, Garibaldi M, Roberto M, Merlonghi G, Pellegrini P, Marchetti P. A Case of Pathological Complete Response and Resolution of Dermatomyositis Following Neoadjuvant Chemotherapy in HER2-Positive Early Breast Cancer. Current Oncology. 2021; 28(3):1957-1961. https://doi.org/10.3390/curroncol28030182

Chicago/Turabian Style

Piras, Marta; Panebianco, Martina; Garibaldi, Matteo; Roberto, Michela; Merlonghi, Gioia; Pellegrini, Patrizia; Marchetti, Paolo. 2021. "A Case of Pathological Complete Response and Resolution of Dermatomyositis Following Neoadjuvant Chemotherapy in HER2-Positive Early Breast Cancer" Curr. Oncol. 28, no. 3: 1957-1961. https://doi.org/10.3390/curroncol28030182

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop